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Abstract
The mammary epithelium undergoes cyclical periods of cellular proliferation, differentiation
and regression. These processes are under the control of the hormones secreted during
pregnancy, lactation and involution. Signaling pathways have been identified that connect
the hormonal stimuli with the transcription of genes responsible for the determination of the
cellular fate. The kinetics of induction and deinduction have suggested that cytokine-
activated Stat proteins play a crucial role. Stat5 is strongly activated towards the end of
pregnancy, persists in an activated state during pregnancy and is rapidly inactivated after
cessation of suckling. Stat3 activation is hardly detectable during lactation, but is strongly
induced at the onset of involution. The phenotypes of mice in which these genes have been
inactivated through homologous recombination corroborate some of the functional
assignments deducted from the activation pattern. Stat3 activation seems to be a driving
force in the induction of apoptosis early in the involution period.
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Signaling pathways and new opportunities for
drug discovery
Nearly all cellular decisions are determined by extracellular
signals (eg hormones, growth factors, surface proteins of
neighboring cells or extracellular matrix components).
These signals are thought to be converted into enzymatic
activities and patterns of gene transcription that determine
the functions and phenotypes of cells. Signal transduction
is controlled by intracellular signaling cascades and the
regulation of latent transcription factors. The identification
of crucial components, such as specific receptors for
signals at the cell surface and linked signal transduction
molecules, has led to a basic understanding of, for
example, the function of growth factors such as epidermal
growth factor or platelet-derived growth factor, hematopoi-
etic cytokines, hormones recognizing receptors coupled
to G proteins and steroid hormone action.
Although we are still far from a comprehensive picture —
especially, the identification of postulated, decisive target
genes specifying particular cellular parameters is not suffi-
ciently advanced — the concept has proven valuable. Linear
chains of events have been described that link defined
extracellular signals to the transcription of individual genes.
These insights have nourished the confidence that a
network of interactions can be established which will allow
very specific modes of interference and the development of
new anticancer drugs. These drugs should preferentially
target the growth propelling signals in a population of
tumor cells with particular genetic abberations, or alterna-Breast Cancer Research    Vol 2 No 3 Groner and Hennighausen
tively activate cellular suicide programs. It is hoped that the
principle exemplified by tamoxifen can be emulated. A
growth limiting step, in this case the activation of the estro-
gen receptor, can be identified and exploited for targeted
interference. In the most favorable cases, this step is rather
restricted to the regulation of the growth of tumor cells,
thus its inhibition will cause few undesirable side effects.
Stat 3 and the regulation of apoptosis in
hematopoietic and mammary epithelial cells
A prerequisite for such an approach is the detailed under-
standing of the function of individual signaling pathways in
normal cells and the consequences of their deregulation in
specific cell types. Especially, signals regulating such basic
cellular properties as survival, proliferation, differentiation
and apoptosis have caught the fancy of molecular oncolo-
gists. If individual signaling components prove to be rate
limiting for such complex genetic programs, they would
constitute outstanding drug targets. Important progress
has also been made in the development of the tools that
allow the evaluation of such molecules. Inactivation of indi-
vidual genes in embryonic stem cells by homologous
recombination and observation of the consequences of
such a mutagenic event in animals is the method of choice.
Chapman et al have applied this technology to the investi-
gation of a member of the Stat family of transcription
factors (Stat3) in the context of the mammary gland [1].
Stat factors are latent transcription factors and comprise a
family of seven genes encoding proteins of similar domain
structures and modes of activation. They are activated by
receptor-associated cytoplasmic tyrosine kinases (Jak)
through phosphorylation on a single tyrosine residue.
Phosphorylated Stat molecules can form dimers, translo-
cate to the nucleus, bind to specific response elements in
the promoter of target genes and alter the rate of trans-
cription [2,3].
Stat3 was originally discovered as the acute phase
response factor, a transcription factor activated by IL-6
and its receptor in liver cells [4]. Subsequently, many
signals have been shown to relay their effects through
Stat3. The hint that Stat3 might also regulate growth prop-
erties of cells came from studies which showed that cellu-
lar transformation with transfected oncogenes or infection
with tumor viruses were often accompanied by the consti-
tutive activation of Stat3, along with Stat5 and, some-
times, Stat1. The use of dominant negative variants of
Stat3 showed that at least NIH 3T3 cell transformation by
v-src is dependent on the function of Stat3 [5]. A Stat3
variant with two amino acid substitutions functions as an
oncogene in tissue culture cells and nude mice [6]. Con-
stitutive activation of Stat3 was also found in primary
human leukemia cells, further implicating Stat3 in the
process of malignant transformation [7].
These observations were complemented by investigations
into the connections between Stat3 and apoptosis regula-
Figure 1
Stages of mammary gland development. (a) The development of the mouse mammary gland can be divided into five stages (pregnancy, parturition,
lactation, weaning, involution) and crucial hormonal components required for each transition have been identified [22]. Placental lactogen (PL)
concentrations increase during pregnancy, and prolactin (Prl) and oxytocin (OT) concentrations rise during lactation, sharply declining after
weaning. P13, pregnancy day 13; i1, involution day 1; i2, involution day 2; i3, involution day 3. (b) Histological whole mount analysis of mouse
mammary gland from virgin mice, pregnant, lactating and involuting mice. Mammary tissues from virgin mice (upper left panel), mice at day 11 of
pregnancy (upper right panel), day 2 of lactation (lower right panel) and day 7 of involution (lower left panel) were fixed and stained with Carmine
Red. Extensive cellular proliferation occurs during pregnancy; quiescent, terminally differentiated secretory alveolar cells are responsive to the
lactogenic hormones and responsible for milk production during lactation; massive cell death characterizes the involution phase.
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tors. A complex network of cytokines, receptors, cytoplas-
mic signaling molecules and transcription factors control
this process, and members of the Bcl-2 family of proteins
play central roles in the regulation of apoptosis [8]. A
balance of pro- and anti-apoptotic influences determines
the outcome. Disturbances in this balance may confer
resistance to physiological signals of apoptosis and lead
to cellular transformation. The induction of Stat3 by IL-6 in
myeloma cells has been shown to protect these cells from
apoptotic stimuli emanating from the Fas (CD95/Apo-1)
receptor or chemotherapeutic agents [9]. In this cell type,
Stat3 activation results in the transcriptional induction of
the bcl-x gene promoter and high levels of the anti-apop-
totic protein Bcl-xL. Thus, elevated levels of Stat3 appear
to contribute directly to malignancy in multiple myeloma
cells by the prevention of apoptosis [10,11].
The mammary gland is a favorable organ to study molecu-
lar mechanisms governing apoptosis (Fig. 1a). Pregnancy
induces massive proliferation of mammary epithelial cells
and the development of alveolar structures. The differenti-
ated secretory epithelium produces large amounts of milk
during the suckling and lactation period [12]. Gene dele-
tion studies in mice have demonstrated that Stat5a is
required for cell proliferation, differentiation and survival
during pregnancy and lactation. After cessation of suck-
ling, Stat5 is rapidly inactivated and the lobulo-alveolar
structures collapse and reductive remodeling of the gland
sets in (Fig. 1b). This involution period is characterized by
proteolytic degradation of the extracellular matrix and elim-
ination of the majority of the secretory epithelial cells by
apoptosis [13,14]. If Stat3 has a role in this process and
acts in a similarly anti-apoptotic fashion as myeloma cells,
one might expect it to be activated during the lactation
period and downregulated during involution. The observa-
tion that activated Stat3 is not detectable in the lactating
gland but induced shortly after cessation of suckling
(Fig. 2) suggests otherwise. Advanced knockout technol-
ogy showed that Stat3 actually fulfills the opposite func-
tion in these cells, ie it promotes apoptosis in the
postsuckling state.
Chapman et al arrived at this conclusion through observa-
tion of a mouse strain in which the Cre–lox recombination
system has been directed towards the elimination of Stat3
function, specifically in mammary epithelial cells. For this
purpose, the Cre recombinase was expressed under the
control of the beta-lactoglobulin gene promoter, a promoter
that is fully activated in differentiated mammary epithelial
cells under the control of lactogenic hormones [15]. The
Stat3 gene was present in a heterozygous state. One allele
was inactivated through standard homologous recombina-
tion (a null allele) [16], the second allele was floxed, ie loxP
sites were introduced around the tyrosine phosphorylation
domain [17]. These loxP sites recombine in the presence of
Cre recombinase, which results in the deletion of the tyro-
sine phosphorylation domain and the inactivation of the
second allele. Chapman et al show that this process occurs
efficiently in differentiated lobular alveolar cells, initially
without phenotype. Upon cessation of suckling, however,
they observe that the wild-type cells, capable of Stat3
induction, show a much higher level of apoptosis and a
more rapid onset of involution. Protection from apoptosis in
Stat3-deficient epithelial cells is transient and involution sets
in with a delay of about 3 days. Eventually, it catches up the
involution process observed in mice with an intact Stat3
pathway. Unlike in myeloma cells, where Stat3 activates the
bcl-x gene, encoding a survival protein and protecting
against apoptosis, the bcl-x gene does not appear to be a
target gene in mammary epithelial cells.
Cooperation of signaling pathways
Examination of additional molecular parameters that might
explain this delay in apoptosis induction in Stat3-deficient
Figure 2
Hormonal signals and the activation of transcription factors mediating
mammary gland development. During the pregnancy stage, alveolar
density continuously increases. Towards the end of pregnancy, starting
at day 13, Stat5a/b are induced by tyrosine phosphorylation and can
be detected in their DNA binding configuration. Activated Stat5
persists during lactation, but rapidly declines after cessation of
suckling [23]. Activated Stat3 is not detectable during the lactation
phase, but is rapidly induced to maximal levels several hours into the
weaning period [24]. Within the same time, the levels of bcl-x and bax
increase [25]. Milk protein synthesis (WAP) and alveolar density
decrease during involution.mammary epithelium turned up two interesting differences
between the Stat3 expressing and nonexpressing glands.
The activated Stat5 molecule is usually rapidly inactivated
upon cessation of suckling, a process triggered by the
lack of the suckling stimulus and a decrease in the circu-
lating level of prolactin [18]. The forced expression of an
activated Stat5 variant in the mammary cells seems pro-
tective against apoptosis at this stage. The observation in
the paper that Stat5 persists longer in the Stat3 non-
expressing cells than in the wild-type cells may hint at an
underlying mechanism for apoptosis protection. A connec-
tion between the regulation of individual members of the
Stat family, ie a hierarchy of action, downregulation of
Stat5 in the presence of Stat3, could be envisaged. Alter-
natively, Stat3 could generate a growth promoting signal
that results in the induction of apoptosis in the absence of
a complementary survival signal. Analogous observations
have been made in oncogene expressing cells in the
absence of serum. This process could accelerate the
death of mammary epithelial cells in Stat3 expressing mice
and slow it down, but not prevent it, in Stat3-deficient
mice. The second interesting possibility discussed
involves the levels of IGFBP-5. This protein might be
induced by Stat3, sequesters IGF-I and prevents the acti-
vation of the IGF-I receptor. The activated receptor exerts
a strong anti-apoptotic action [19,20].
The conclusion that Stat3 can exert an anti-apoptotic
effect in myeloma cells and a pro-apoptotic effect in
secretory mammary epithelial cells seems initially contra-
dictory. Although dealing with different cell types, it seems
unlikely that they should have developed opposing mecha-
nisms of apoptosis regulation. Differential effects of a
single signal on distinct cell types, however, are not
unknown. Glucocorticoid hormones, for example, are
potent inducers of apoptosis in lymphocytes, but do not
kill fibroblasts or epithelial cells. Even slight proliferative
responses to the hormone have been observed in these
cell types. The c-myc gene can contribute to proliferation
and transformation in cells grown under serum conditions,
but can induce apoptosis if a serum derived signal is
missing [21]. High levels of activated Stat3 are not only
observed during involution, but also during puberty, a time
of rapid ductal growth and branching. This suggests that
Stat3 may serve additional functions during puberty,
which will be uncovered upon deletion of the Stat3 gene
in mammary tissue at earlier developmental stages. The
use of a Cre gene under control of the mouse mammary
tumor virus long terminal repeat, which is already active in
early ductal structures, should provide further insight.
The key to the understanding of differential and cell-
specific effects might be found in the integration of signals
and activated pathways that each cell type encounters at
any time. Lateral signaling, ie the activation of receptors
through unconventional ligands, and the intracellular inter-
action and cooperation of signaling components will com-
plement our picture of linear pathways in the future. In addi-
tion, duration and intensity of signals have to be taken into
account. The diversity of signaling-induced phenotypes
through cooperation of signaling pathways and compo-
nents is still poorly appreciated. These parameters will
provide explanations for cell type specific effects of individ-
ual signaling components and a code of signal interactions
might ensue. This might become comparable with other
codes used in cells to generate diversity through combina-
torial mechanisms from a limited set of components. Its elu-
cidation will certainly be labor intensive, but potentially
rewarding since it increases the possibilities for targeted
interference and the development of useful drugs.
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